Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.

Clin Cancer Res · 2024 · PMC11609625 · PMID 39385434

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

showed a trendP = 0.061so close (0.05 < p ≤ 0.1)

IL6 baseline levels below the median (1.8 pg/mL) showed a trend for a favorable OS ( P = 0.061) (Supplementary Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.